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ABSTRACT 
 
Author: Jihyun Byun 
Title: Characterization of Harm Reduction Services for Intravenous Drug Users in Austin, TX 
Supervising Professor: Dr. Steve Steffensen, Dell Medical School 
The opioid crisis is garnering more and more attention due to the unprecedented number of 
overdose fatalities. However, in addition to the threat of overdose, intravenous (IV) drug users 
face an increased risk of morbidities such as viral and bacterial infections. These include HIV, 
Hepatitis C, skin and soft tissue infections, and endocarditis (inflammation of the heart’s inner 
lining), which may require invasive and costly treatment. Harm reduction is a strategy that 
presents an alternative to abstinence-only focused interventions and aims to ameliorate some of 
the adverse consequences of drug use. The most common harm reduction strategies for IV drug 
users include distribution of overdose reversal medication and clean needles to prevent 
infections; these strategies have proven to be safe and effective but have not been widely 
implemented.  
An organization called the Austin Harm Reduction Coalition (AHRC) serves the local IV drug 
user population by providing several medical services, including needle distribution. This project 
seeks to characterize AHRC’s efforts and impact through analysis of anonymous surveys 
completed by their patient population. Demographic information, population indicators, and 
health statistics will provide greater insight into the needs and attributes of a uniquely vulnerable 
population and further inform efforts to reduce morbidity and mortality among IV drug users. 
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BACKGROUND 
 
Opioid Crisis: Causes, Trends, and Risk Factors 
The National Institute of Health states, “Opioids are a class of drugs that include the illegal drug 
heroin, synthetic opioids such as fentanyl, and pain relievers available legally by prescription, 
such as oxycodone (OxyContin), hydrocodone (Vicodin), codeine, morphine, and many others.”1 
Opioids possess addictive properties because they produce feelings of euphoria in addition to 
providing pain relief.  
Though there is insufficient evidence to support the safety and efficacy of the long-term use of 
opioids to treat chronic pain,2 the most commonly reported reason for their misuse was physical 
pain relief.3 The National Survey on Drug Use and Health revealed that 80% of current heroin 
users indicated that their substance use disorder began with opioid pain relievers.4  
Most people (50.5%) who report abusing opioids state that they obtained them from a friend or 
relative for free.5 Pharmaceutical companies’ aggressive promotional efforts and inaccurate 
claims led to a sharp increase in opioid prescriptions and their subsequent proliferation 
nationwide. At its peak, the annual opioid prescribing rate was 81.3 per 100 persons in 20126 as 
shown in the figure below. 
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Figure 1 -  National prescribing rate of opioids from 2006 to 20176 
 
Though updated recommendations and training programs for healthcare providers have improved 
prescribing practices, the number of opioid prescriptions remains high, at 58 prescriptions 
written for every 100 Americans. 
In 2017, the acting Health and Human Services Secretary declared the opioid crisis a national 
public health emergency.7 11.5 million adults reported misusing a prescription opioid at least 
once in 2015, and almost 2 million had a use disorder.3 From 1999-2017, almost 400,000 people 
died from opioid overdoses,3 and in 2017, the number of opioid overdose deaths exceeded the 
number of yearly fatalities caused by HIV/AIDS, motor vehicle accidents, or gun violence at 
their peaks.8 
After patients become dependent on opioid pain relievers, many turn to heroin, as it is much less 
expensive to obtain.9,10 Heroin and other opiates have higher overdose fatality rates than other 
drugs.8 They affect the regions of the brain that control respiration, and at high enough doses, 
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may cause slow and ineffective breathing,8 which limits the amount of oxygen available to the 
body and brain, possibly leading to coma, brain damage, and even death.11 
Historically, fatalities can be attributed to three distinct waves that follow the prevalence of 
prescription opioids, heroin, and synthetic opioids.6 
 
Figure 2 - Waves of the Rise in Opioid Overdose Deaths from 1999 to 20176 
A widely prevalent synthetic opioid is fentanyl, a pain-relieving drug that is 50-100 times more 
potent and powerful than heroin. It is often added to heroin because it provides a stronger high 
for a cheaper price.11 Many drug users are unaware that their heroin is cut with fentanyl, putting 
them at high risk for an overdose.12 Recently, the number of deaths caused by synthetic opioid 
overdose has sharply increased as illustrated in the figure above, a trend present in all regions 
and demographic groups.13 Fentanyl is now the primary or contributing cause of death in over 
half of all overdose fatalities, with about a third of deaths occurring in young adults.14 The DEA 
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states that “fentanyl is the most prevalent and significant synthetic opioid threat to the United 
States and will very likely remain the most prevalent synthetic opioid threat in the near term.”10  
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Demographic Characteristics of the Opioid Crisis 
 
Though the opioid epidemic has affected all demographic and socioeconomic groups,15 it has had 
a disproportionate impact on disadvantaged populations.  
Table 1 - Annual average rate of heroin use per 1,000 people in each demographic group for 2002-2004 and 2011-
201316 
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As the table above indicates, heroin use is more prevalent among men than women and among 
young adults than other age groups. Non-Hispanic whites, low-income individuals, and those 
without health insurance also have the highest rates of use.  
In addition, opioid misuse and use disorders were more commonly reported in those suffering 
from mental illnesses and other substance use disorders.3 Though overdose fatalities are 
increasing across all racial groups, non-Hispanic whites have the highest death rates.  
 
Figure 3 - Drug Overdose Mortality by State 17 
 
The Northeast and Midwest regions of the U.S. have experienced the most significant increases 
in overdose deaths.18 Low education levels and high rates of unemployment and job-related 
injuries that are characteristic of these areas contribute to an increased risk of opioid abuse.19 
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Co-morbidities of Opioid Abuse 
 
In addition to the danger of overdose, IV drug users are susceptible to a variety of co-
morbidities, such as viral and bacterial infections such as human immunodeficiency virus (HIV), 
Hepatitis C, soft tissue and skin infections, and endocarditis.  
 
• HIV 
HIV attacks and destroys the infection-fighting cells of the immune system,20 and without 
treatment, can lead to acquired immunodeficiency syndrome, or AIDS.21 IV drug users are at 
increased risk of infection with HIV from unsafe injection practices such as sharing equipment 
used to prepare and inject drugs (e.g. needles, cotton, and cookers) as they may be contaminated 
with blood that carries HIV.22 The CDC estimates that 1 in 10 HIV diagnoses are among people 
who inject drugs23 and projects that 1 in 23 and 1 in 36 women and men who inject drugs, 
respectively, will be diagnosed with HIV in their lifetime.24 
 
• Hepatitis C  
Hepatitis C is a virally transmitted disease. Approximately 80% of infected persons develop a 
chronic infection that may lead to liver damage, liver failure, and even liver cancer.25 Like HIV, 
IV drug users face an increased risk of infection from unsafe injection practices. The Hepatitis C 
virus (HCV) is highly infectious and can easily spread when a person comes into contact with 
surfaces, equipment, or objects that are contaminated with infected blood, as the virus can 
survive on dry surfaces and equipment for up to six weeks. In the U.S., IV drug use is the 
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primary risk factor for Hepatitis C virus transmission and is the leading cause of incidence.23 
Opioid injection rates are closely correlated with reported cases of acute HCV infection, which 
suggests that national increases in acute HCV infection is related to the country’s epidemic of 
opioid abuse.26 The annual HCV incidence in young adult IV drug users is approximately 27%.27 
 
• Bacterial infection 
Bacterial infection is a lesser-known problem that intravenous (IV) drug users experience, which 
can range in severity from skin and soft tissue infections (SSTI) to endocarditis (inflammation of 
the heart’s inner lining). Skin and soft tissue infections are the most common types of infections 
found in drug users; a majority of SSTI and endocarditis cases are caused by an organism that is 
part of the skin’s normal flora28 but becomes an opportunistic pathogen when the skin is 
breached. 
Cutaneous and subcutaneous abscesses (a buildup of pus in the skin) are the most common 
symptom of SSTIs and typically occur when drug users inject directly into skin or muscle when 
they cannot find a suitable intravenous injection site.29,30 The lifetime reported prevalence of 
SSTI among IV drug users was 58%, 30% for a 1-year period, and 14% for a 30-day period.31 
The national cost estimate for treating SSTIs from IV heroin use in 2001 was $193 million.32 
Infective endocarditis is a condition that presents serious complications with significant 
morbidity and mortality rates.33 The annual incidence of endocarditis among IV drug users in the 
United States ranges between 1–5%.34 IV drug use is the main risk factor for endocarditis, 
especially in urban areas and among younger patients.35 Like Hepatitis C, hospitalizations for 
endocarditis are correlated with increased rates of opioid use; one study found that the annual 
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incidence of hospital discharge diagnoses for patients with drug dependence and endocarditis 
increased from 0.2 to 2.7 per 100,000 persons over 2010 to 2015, and that the cost of treatment 
for those patients rose during that time period from $1.1 to $22.2 million.36 Overall, national 
rates of drug injection-related infections (e.g. SSTI, endocarditis and hepatitis C) are rising.37, 38, 
26 
 
• Collapsed Veins 
Repeated injection can irritate and damage the inside of a vein; swelling and clots that form near 
the damaged areas may block the vein, which can cause loss of circulation, sharp pain, and 
discoloration of the skin. Risk factors for vein collapse include poor injection technique, 
presence of debris, and the use of blunt needles.39 
 
• Cotton Fever 
A lesser-known illness that IV drug users experience is colloquially called “cotton fever”, a 
condition characterized by symptoms that may include fever, chills, headache, nausea, and pain 
after injecting a drug solution filtered through cotton.40 
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Variations of Risk Factors from Heroin Type 
 
In the U.S., heroin is sold in three main forms: white powder, brown powder, and as a black 
sticky substance known as “black tar.” The DEA reports, “The heroin market in the United 
States has been historically divided along the Mississippi River, with western markets using 
Mexican black tar and brown powder heroin, and eastern markets using white powder heroin.41  
  
Each type of heroin has unique qualities that lend themselves to different risks associated with 
their use. Thus, there are distinct geographic distributions in their co-morbidity profiles.42 
 
• Fentanyl and Risk of Overdose 
Fentanyl is most commonly mixed with white powder heroin or is sold disguised as white 
powder heroin.41 As such, the areas affected most by fentanyl overdoses are in the Eastern 
United States, where white powder heroin is more prevalent. One researcher stated, "Despite the 
large differences in deaths across states, there's no evidence to suggest that there's differences in 
[heroin] use. What we think is happening is that the heroin just continues to get more and more 
potent in the Eastern United States, whereas heroin [in] the Western United States has 
Figure 4 –From left to right: brown powder, white powder, and black tar heroin42 
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traditionally been this brown tar heroin. It's much harder to lace with fentanyl or other synthetic 
opioids."43 
 
• SSTI 
Black tar heroin, the form of heroin predominantly found in southern and western states, is 
responsible for higher rates of SSTI than powder forms of heroin because of its high moisture 
content and high contamination rates. In addition, black tar heroin is often subcutaneously 
injected due to its viscosity, which, as stated earlier, is a major risk factor for abcesses.30 Not 
surprisingly, cities predominantly supplied with black tar heroin had 40% higher rates of SSTI 
compared to their powder heroin-supplied counterparts.44,37 
 
• HIV 
Black tar heroin is correlated with a reduced risk of HIV infection since its unique physical 
properties require utilization of relatively safer injection practices.45 
o Viscosity - Due to black tar heroin’s high viscosity, syringes used for injection 
need to be frequently rinsed and flushed out to prevent clogging, which leads to a 
reduction of residual blood volume in the syringe. One study found that rinsing 
blood-contaminated 1 mL syringes with water resulted in a 74% to 92% reduction 
in residual blood volume following a single rinse,46 which consequently 
diminishes the likelihood of transmitting HIV if a contaminated syringe is 
reused.47 
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o Solubility – the solubility of black tar heroin is much lower than white powder 
heroin. As such, it needs to be heated at higher temperatures and longer durations 
to dissolve into solution, which reduces the level of HIV particles.48 
 
o Venous sclerosis (the loss of functioning veins) is more commonly attributed to 
black tar heroin due to its acidity.44 Venous sclerosis forces IV drug users to 
transition from venous injection to subcutaneous or intramuscular injections,47 
which significantly reduces the transmissibility of HIV.49 Accordingly, IV drug 
users in cities with predominantly black tar heroin had a lower prevalence of HIV 
than those in cities with predominantly powder heroin.47 
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Treating Opioid Addiction 
 
There are three FDA approved medications to treat opioid use disorder — methadone, 
buprenorphine and naltrexone. These drugs are opiate agonists and bind to opiate receptors in the 
brain to reduce cravings without causing a high.50 The figure below illustrates their mechanism 
of action. 
 
Figure 5 – Opiate Use Disorder Medications’ Interactions with Opioid Receptors in the Brain51 
Research supports opioid agonist therapy as the most effective treatment for opioid use disorder, 
and has shown that it is cost-effective, increases treatment retention, improves long-term health 
outcomes, and decreases drug use, relapse, transmission of infectious diseases, criminal activity, 
and overdose deaths.18 
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Availability of Opioid Addiction Treatment 
 
Medication-Assisted Treatment (MAT), which combines opiate agonist therapy with behavioral 
therapy, is considered the “gold standard” of opioid addiction treatment and has demonstrated 
effectiveness in patient recovery.52 However, many are unable to access its benefits, and 
significant gaps exist between the needs of those who suffer from an opioid use disorder and the 
treatment capacity of recovery programs.53 A federally funded report found that approximately 
80% of the two million people with an opioid addiction in the U.S. are not being treated with 
MAT despite its potential to reduce overall mortality rates by half or more.54 Furthermore, only 
about a quarter of publicly funded treatment programs and less than half of private treatment 
programs reported offering FDA-approved medication to treat substance abuse.55  
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One study found that the estimated number of Texas residents with an opioid addiction exceeded 
patient capacity by 4.4 people per 1,000 residents.56 
 
Figure 6 –Potential Areas in Texas for Addressing Service Gaps for Opioid Treatment57 
The figure above displays areas (as indicated by a dark red overlay) that have the greatest need 
for MAT services; most notably, many of them are clustered around the perimeter of large cities. 
 
• Limited insurance coverage 
Medicaid is an essential conduit for MAT access. One study found that “states that expanded 
Medicaid have seen a greater uptake in the amount of buprenorphine prescribed, averaging a 70 
percent increase. Conversely, states that did not expand Medicaid have seen little or no increase 
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in buprenorphine prescriptions.”58 Medicaid expansion has also played an important role in 
reversing overdoses – the number of Medicaid-funded Naloxone prescriptions increased from 
10,000 to 120,000 units between 2011-2016.58 
 
• Lack of qualified medical personnel 
Methadone is associated with better retention rates than buprenorphine and naloxone.59 
However, it can only be provided in certified opioid treatment programs,60 not in primary care 
settings, which presents an access barrier for many patients.61 As of March 2019, there were 
about 1 million practicing physicians in the U.S.54 Of those, only about 65,00062 – approximately 
6.5% – possess the necessary waiver to prescribe buprenorphine, and even then, can only treat a 
limited number of patients for opioid abuse. Thus, the number of people with opioid dependence 
far exceeds the number of eligible providers who can prescribe buprenorphine for opioid use 
disorder,53 especially in rural areas.  
Only naltrexone is available for prescription by primary care providers; however, because it 
requires the patient to undergo full detoxification, initiation of treatment is often more difficult.63 
Policy experts recommend legislative changes that will allow healthcare professionals greater 
freedom to prescribe all three approved opioid antagonists.  
 
• Stigma 
Restriction and limited utilization of opioid agonists comes in part from fears of its abuse since 
methadone and buprenorphine are also opiates. One Health and Human Services secretary stated, 
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“If we’re just substituting one opioid for another, we’re not moving the dial much.”64 Though it 
is possible for patients to overdose with methadone, his statement directly contradicts the 
addiction science community’s consensus on the important role of medication-assisted treatment. 
In addition, many unfounded views are propagated by organizations with abstinence-only 
philosophies.  
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Harm Reduction 
 
• Overview 
Harm reduction is a strategy that presents an alternative to abstinence-only focused interventions 
and aims to ameliorate some of the adverse consequences of drug use. The co-morbidities 
outlined earlier, such as HIV, hepatitis C, and bacterial and viral infections, can be prevented by 
providing IV drug users with clean needles and disinfectant, a simple, cost-effective solution that 
has demonstrated efficacy in pilot studies. 
 
• History 
In many other parts of the world, such as Western Europe, harm reduction services have been 
widely available since the early 1900’s. However, the U.S. has traditionally taken a prohibitionist 
focus and has operated under the assumption of abstinence, which delayed the implementation of 
harm reduction programs for several decades.65  
Progress can be attributed to the efforts of activists, who provided data to justify harm reduction 
programs implemented by local governments that were paramount in curbing the HIV epidemic 
among IV drug users. Harm reduction programs were first piloted in New York, Washington, 
and Connecticut; all resulted in infectious disease transmission reduction for their respective 
patient populations. Though syringe exchange programs were created to reduce the transmission 
of infectious diseases, they quickly expanded to provide additional supplies and services such 
disease counseling and testing, naloxone to treat overdose, safer sex supplies, and referrals to 
substance abuse treatment.  
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• Elements of Harm Reduction 
 
o Distribution of Overdose Medication - naloxone is an inexpensive, generic drug 
that works to reverse an overdose by blocking opioid receptors in the brain and 
reversing the effect of opioids.66 It cannot be abused and has demonstrated safety 
and efficacy in a wide variety of settings. From 1996 to 2014, almost 27,000 
people in the U.S. were saved from overdose with the administration of naloxone 
distributed by community-based programs.67 However, significant barriers remain 
in making naloxone widely available among the IV drug user community and the 
people around them.  
 
o Needle exchanges accept used syringes and distribute new, sterile ones. In 
addition to reducing the transmission of infectious diseases and helping to protect 
the skin and vein integrity of IV drug users, they also prevent syringes from being 
discarded in locations where they pose a threat to the public, especially children. 
In 2015, only 1 in 4 IV drug users obtained all their syringes from sterile sources. 
Studies have shown that sharing needles is influenced by peer group behavior, 
individual attitudes, economic barriers, not owning injection equipment, and 
fatalism about developing AIDS.68 
 
o Providing supplies for safer injection practices – studies have shown that the 
incidence of subcutaneous abscesses and endocarditis was lower among IV drug 
users who reported skin cleaning all the time and concluded that “the relatively 
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simple procedure of encouraging intravenous drug users to clean their skin prior 
to injection will not eliminate but might reduce the frequency of these serious and 
expensive infectious complications of intravenous drug use.”69 In addition to skin 
cleaning, the CDC also recommends the use of sterile water to prepare drugs to 
reduce HIV transmission.70 
 
o Good Samaritan laws provide prosecution immunity for people who call for help 
with an overdose; though most states have them in some form, they vary widely 
in the scope of the protections they provide. Policy experts recommend that these 
laws be expanded to “reduce as many barriers to calling 911 as possible, including 
arrest, parole or probation violations, and immigration or child welfare 
consequences.”71 
 
o Supervised consumption services provide safe, medically monitored spaces where 
people can consume drugs. They help reduce many problems associated with drug 
use and can act as a conduit to provide hard-to-reach populations with treatment, 
care, and possibly emergency services. They reduce the danger of fatal overdose 
and the transmission of blood-borne pathogens.   
 
o Drug checking is a procedure that is used to identify adulterants in drugs, namely 
fentanyl in heroin. The test is simple and involves visual inspection of a fentanyl 
testing strip. Awareness of adulterants helps drug users exercise caution and make 
more informed decisions about their drug consumption.  
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• Efficacy and Results 
Many studies across a wide variety of settings have found that needle exchanges are one of the 
most cost-effective public health interventions. In addition to reducing infectious disease 
transmission among IV drug users72 without increasing or enabling drug use,65 they connect 
users to recovery programs and reduce criminal activity.73  
 
• Federal Support and National Strategies 
The Substance Use Disorder Prevention that Promotes Opioid Recovery and Treatment for 
Patients and Communities (SUPPORT) Act was signed into law by President Trump in late 
2018. It broadens Medicaid’s capacity to provide services to people with substance use disorders 
and includes the following features:  
o Requires state Medicaid programs to cover all aspects of medication-assisted 
treatment (FDA-approved drugs, counseling services, and behavioral therapy) 
o Lifts the ban on the use of federal Medicaid funds for services provided in mental 
health institutions   
o Facilitates access to coverage and care for former prison inmates  
o Facilitates increases in substance use disorder provider capacity for states with a 
high prevalence of opioid use disorder by providing additional funding 
o Requires states to have drug monitoring programs by 2021 
o Requires state Medicaid programs to provide an annual report on behavioral 
health quality measures 
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Though most health policy experts conceded that the SUPPORT Act was a step in the right 
direction, they claimed that it was ultimately an insufficient response to the magnitude of the 
opioid crisis: 
o “This [act] reflects a fundamental disagreement between the parties over whether 
the government should appropriate the large sums a massive response would 
require… lacking that, Congress did the next best thing — which is to find 
agreement on as many second-tier issues as they could.”74 
o “Despite reauthorizing and creating some small grant programs, it won’t result in 
much more money and resources going to the opioid crisis.”75 
o “The law is notable for what it does not include, most prominently, a major, 
sustained infusion of new funding to expand community-based care for substance 
use disorders.”76 
 
• State Strategies 
Independent from the federal SUPPORT Act, many states have implemented a variety of 
strategies and programs to reduce the number of injuries and fatalities associated with opioid 
overdose. Successful interventions include:  
 
o Prescription monitoring programs – implementation of a monitoring program to track 
opioid prescribing resulted in an average annual reduction of 1.12 opioid-related 
overdose deaths per 100,000 population.77 Every state except for Missouri has a 
monitoring program. 
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o Investing in harm reduction – 21 states and the District of Columbia have laws 
authorizing syringe exchange programs, either state-wide or in limited areas or 
situations; 29 states do not.78 
 
o Expanding Medicaid – as was mentioned above, there was a significant increase in 
prescriptions for medication used to treat opioid abuse in expansion states; 
interestingly, these states only saw a marginal increase in opioid prescriptions.79  
 
• Harm Reduction in Texas 
 
o Needle Exchanges – Under Texas’s Health and Safety code, needle exchanges are 
illegal – regarding possession of drug paraphernalia, the Texas Controlled 
Substances Act states: 
A person commits an offense if the person knowingly or intentionally uses 
or possesses with intent to use drug paraphernalia to plant, propagate, 
cultivate, grow, harvest, manufacture, compound, convert, produce, 
process, prepare, test, analyze, pack, repack, store, contain, or conceal a 
controlled substance in violation of this chapter or to inject, ingest, inhale, 
or otherwise introduce into the human body a controlled substance in 
violation of this chapter.80 
However, following increasing morbidity rates associated with unsafe injection 
practices and the support of a growing body of research regarding the safety and 
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efficacy of harm reduction practices, legislators have supported bills that seek to 
establish pilot needle exchange programs. Using the categorical search function in 
the Texas Legislature’s website, all filed bills regarding needle exchanges in the 
past two decades were identified. As of April 2019, there have been 22 bills 
regarding needle exchanges.  
 
 
Figure 7 - Bill Stages for HB28881   
As the diagram above indicates, a bill must pass through six stages before it 
becomes law. Of the 22 needle exchange bills, only four reached the second stage, 
only two reached the third stage, and only one reached the fourth. Failure of these 
bills to become law is attributable to a variety of reasons, such as late placement 
 
29 
 
on a hearing calendar, the opposition of senior legislators, or objections of 
committee members to which it is assigned.  
o Opioid Overdose Reversal Medication – with the passage of a bill in 2015, it 
became legal in Texas to obtain naloxone without a prescription, which allows 
those in close proximity to opioid abusers, such as friends and family members, to 
have access to potentially lifesaving medication in case of an overdose.82  
 
o Good Samaritan Law – Also proposed in 2015, House Bill 225 would have 
provided “defense to prosecution for certain offenses involving controlled 
substances and other prohibited drugs, substances, or paraphernalia for defendants 
seeking assistance for a suspected overdose.”83 However, it was vetoed by 
Governor Abbott at the last stage and failed to become law.  
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RESEARCH 
 
Austin Harm Reduction Coalition 
 
• Overview 
The Austin Harm Reduction Coalition (AHRC) is a non-profit volunteer-based organization that 
provides harm reduction services for drug users. Their website states, “AHRC works to prevent 
the spread of HIV/AIDS and Hepatitis C for people who inject drugs in Austin, Texas. We 
provide HIV & HCV testing, drug treatment referrals, medical care, overdose prevention and 
resources to prevent disease transmissions such as condoms, alcohol pads, and supplies for safe 
injection. We also provide linkage to care for active drug users who have HIV or Hepatitis C.” 
 
• Organizational History and Structure 
Located in the Central East Austin neighborhood, AHRC has provided harm reduction services 
for more than 20 years. Their overdose prevention program, which includes the distribution of 
overdose medication and training, first began in 2014. AHRC further expanded in 2015 to offer 
HIV and HCV testing, wound care, and linkage to care for HIV or HCV patients.  
Though needle exchanges are illegal in Texas, AHRC coordinators report that the Austin Police 
Department has been tolerant of the organization. Unfortunately, in other Texas cities, needle 
exchange volunteers have faced arrest, effectively shutting down their activities. As such, AHRC 
is the largest needle exchange program in Texas. It is mainly funded through private grants and 
employs a small group of directors and coordinators to support its operations.  
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• Services 
 
Figure 8 – AHRC’s outreach van 
 
Figure 9 – Interior view of AHRC’s outreach van 
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Figure 10 – AHRC’s current outreach locations 
 
o Mobile Outreach – AHRC seeks to provide harm reduction services to areas most 
affected by injection drug use, overdose, HIV and Hepatitis C; as such, they 
utilize a mobile outreach service model to access various locations throughout 
Austin. Pictured above are AHRC’s van and its outreach locations. Outreach vans 
are staffed with one staff member, one medical professional, and two volunteers.  
 
§ Needle exchange - patients enter the van, turning in used syringes that are 
either secured in containers or individually discarded into a large bin. 
After they state how many syringes they turned in, they are then given an 
equivalent number of clean insulin syringes of the length and gauge of 
their choice in addition to a sharps disposal container. If patients do not 
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bring in any used needles, they are provided with a “starter kit”, which 
consists of 10-20 needles. AHRC employs a medical waste company to 
safely dispose of the used syringes after collection. 
 
§ Safe Injection Supplies – AHRC’s patients also have access to additional 
supplies that help prevent disease transmission, which include the 
following: 
 
• Medical-grade sterile saline and water – enclosed in small plastic 
vials, they are used to heat and dissolve drugs into solution before 
injection and present a more sanitary alternative to non-sterile 
sources of water.  
• Rubber tourniquets – used help patients find veins for injection.  
• Long-staple cotton – used to filter the liquid drug solution after 
heating to remove impurities or chunks that did not melt as it is 
drawn up into the syringe.   
• Bottle caps with twist tie handles – serve as containers in which to 
“cook” the drug and turn it into a liquid form for injection. The 
shape of the handle helps protect the patient’s fingers from burns.  
• Alcohol wipes – used to clean the skin near the injection site.  
• Rubber mouth guards and copper wool – methamphetamines and 
cocaine are commonly smoked through small glass tubes. When 
placed over the top of the tube, the guards help protect the mouth 
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from burns or cuts from the hot glass. The copper wool is used to 
separate the burning drug from the vapor and helps keep it in 
place.  
 
§ Overdose Medication - After patients receive their needles, they are asked, 
“Do you need any Narcan (naloxone)?” AHRC reports that they have 
distributed thousands of doses since 2004 and that more than 200 overdose 
reversals have been reported to them. Patients are given a small pouch that 
includes three syringes and vials of intramuscular naloxone and provided 
training and education for recognizing signs of an overdose as well as 
administering the medication.   
 
§ Fentanyl Testing Kit – also included in the pouch with Naloxone 
medication are several fentanyl test strips. After they have cooked their 
heroin and drawn up the solution, patients are encouraged to test the 
residue in their cooker for fentanyl by dissolving additional water into it 
and inserting the test strip, as pictured in the figure below.  
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Figure 11 – Fentanyl test strip distributed by AHRC 
 
§ Drug treatment referrals and linkage to care – several members of 
AHRC’s staff are Licensed Clinical Dependency Counselors. They assist 
patients in enrolling in treatment programs or provide referrals to other 
public assistance programs, such as for primary care or stable housing.  
Because of their frequent outreach efforts, they have built rapport with 
many of their patients and encourage them to seek treatment, further 
lending credence to the fact that harm reduction helps connect people to 
recovery.  
 
§ Medical care – During needle exchange services, AHRC’S patients are 
also asked if they need medical attention for wounds or infections from the 
healthcare professional staffed on the van. In addition to providing basic 
care such as wound cleaning and dressing, they provide patient education 
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on safe injection practices, help patients find veins, and answer questions 
and address concerns of overdose.  
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AHRC Survey Data 
 
AHRC collects patient data through voluntary, anonymous surveys. The survey for needle 
exchange services includes the following information: 
• Site – designates the outreach location at which needle exchange services were provided 
• Patient information: 
o Sex – Male, Female, Transgender Female, Transgender Male, Other 
o Race – Asian, Black, Hispanic, White, Pacific Islander, Multiracial, Other 
o Age  
o Units In (number of syringes turned in) 
o Units Out (number of syringes distributed) 
o Type: Primary or Secondary (designates if needles are being used exclusively for 
the individual patient or also being distributed to another person) 
o Insurance – Federal, Medical Access Program (MAP), Medicaid/Medicare, No 
Insurance, Private, VA, Other 
With permission from AHRC’s director, needle exchange data for 2018 was used to characterize 
the burden of opioid abuse in Austin. Data was first cleaned and categorical variables that 
required manual entry were standardized. Statistical analysis was performed using R software.  
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• Syringes 
Table 2 – summary of descriptive statistics for the number of syringes received and distributed, n=4309 
Variable Sum Median Mean Std. dev 
Units In 380,361 30 88.27 171.98 
Units Out 406,271 40 94.28 137.41 
 
As the table above shows, AHRC facilitated the safe disposal of about 380,000 used needles and 
distributed more than 400,000 clean needles within 4,309 patient encounters. The median 
number of syringes turned in and distributed are 30 and 40, respectively, with large standard 
deviations for both measures.  
The average number of daily injections per IV drug user is estimated to be 2.8,84 which indicates 
that one patient would need about 1,000 needles per year if a clean needle was used for every 
injection. Though the number of patients served by AHRC cannot be precisely calculated 
because the data is not de-duplicated to guarantee anonymity, dividing the number of needles 
distributed by AHRC (400,000) by an estimate of the number of needles required per year per IV 
drug user (1,000) would roughly indicate that AHRC serves the needs of several hundred 
patients per year.  
 
• Demographic information 
As was discussed earlier, there are significant variations in IV-drug-use-associated morbidity and 
mortality between demographic and socioeconomic groups. As such, information collected in the 
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survey was utilized to analyze which groups are most in need of AHRC’S needle exchange 
services, as summarized below:  
 
Table 3 – Demographic characteristics of needle exchange patients served by AHRC in 2018 
 
 
Men have the highest frequency of patient visits (63%). 68% of visits were for white patients, 
while 25% were for Hispanic patients, which roughly aligns with results from nationally 
 
40 
 
representative surveys of opioid use; however, the proportion of older respondents from AHRC’s 
data is significantly higher.  
 
• Insurance Status 
Table 4 - Insurance status of needle exchange patients served by AHRC in 2018 
 
Table 3 indicates that AHRC’s patients are overwhelmingly underinsured, with 59% of 
respondents indicating they did not have any form of insurance, while 19% indicated that they 
are enrolled in the Medical Access Program, which provides health care coverage for low-
income Travis County residents.85 Though there are some safety-net drug recovery programs that 
target underinsured populations, lack of insurance clearly presents a major obstacle for many of 
AHRC’s patients in accessing treatment or adequate medical care for complications that may 
arise from their drug use.  
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• Location 
Table 5 – Number of syringes distributed at each outreach location in 2018 
 
Location Zip Code # of Syringes Distributed 
3rd & Comal 78702 90,241 
Ben White 78704 8,773 
Festival Garden 78702 44,790 
Hancock 78751 28,463 
Mars South 78745 12,290 
MLK and Nueces 78701 49,468 
Planet K 78702 45,864 
William Cannon 78745 21,632 
 
The number of syringes distributed at each outreach location were analyzed to further inform 
AHRC’s outreach efforts and provide insight into which areas have the greatest need for their 
needle exchange services.  
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Figure 12 – AHRC’s 2018 outreach locations 
The Uniform Data System (UDS), a mapping tool from the Health Resources and Services 
Administration, was utilized to map AHRC’s outreach locations onto a population indicator 
overlay; figure 12 indicates that each of the locations is in an area that had a greater proportion of 
individuals living in poverty than the national average.  
 
 
 
 
 
 
 
43 
 
FURTHER CONTINUATION 
 
As mentioned previously, a major limitation to the survey data utilized in this research is that it is 
not de-duplicated; as such, it is difficult to estimate the true proportion of demographic 
characteristics, health statistics, or the burden of disease from co-morbidities associated with IV 
drug use. To examine hospitalization trends associated with complications from drug abuse, 
several studies have utilized data from patients with discharge codes for both drug dependence 
and a condition such as endocarditis.86 Obtaining this data from local safety-net hospitals 
presents a potential avenue to more accurately characterize the burden of drug-associated 
disease.  
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CONCLUSION 
 
Many factors contribute to wide variations in IV drug users’ risks of morbidity and mortality. 
This thesis explores various aspects of harm reduction for this population, including distribution 
of overdose medication, needle exchanges, and supplies for safer injection practices as well as 
state and federal strategies to ameliorate morbidity and mortality of IV drug use. The need of 
treatment programs and medications far exceeds availability, with wide disparities in rural areas 
and disadvantaged populations.  
The efforts and programs of Austin Harm Reduction Coalition, a local organization, were 
characterized and detailed. Data gathered from its needle exchange surveys were analyzed to 
provide estimates of demographic information and health information of Austin’s IV drug user 
population. Results align with nationally representative surveys that indicate that this population 
is largely underinsured; these results may be utilized to better inform AHRC’s outreach efforts 
and tailor its services.  
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